Zobrazeno 1 - 2
of 2
pro vyhledávání: '"O. Amede-Manesme"'
Autor:
Didier Guillemot, Georges France, Pierre Fender, J.-M. Alexandre, O. Amede-Manesme, J.-P. Bader, M. Bouhassira, B. Calles, A. Castaigne, M. Chauvenet, B. Diquet, I. Giri, F. Ichou, P. Jolliet, J.-M. Joubert, J.-P. Lehner, M. Lièvre, H. Mathiex-Fortunet, M. Marty, F. Meyer, J. Micallef, M. Pigeon, B. Rouveix, F. Zannad
Publikováno v:
Therapies. 60:359-362
Resume Des lors qu’un nouveau medicament est susceptible d’etre commercialise, la question de l’evaluation du progres therapeutique se pose en deux temps. Tout d’abord quelle est la quantite de progres therapeutique attendu ? Ce premier temps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::704c586d46360676912a4ca0d32b8247
https://doi.org/10.2515/therapie:2005051
https://doi.org/10.2515/therapie:2005051
Autor:
Didier Guillemot, Georges France, Pierre Fender, J.-M. Alexandre, O. Amede-Manesme, J.-P. Bader, M. Bouhassira, B. Calles, A. Castaigne, M. Chauvenet, B. Diquet, I. Giri, F. Ichou, P. Jolliet, J.-M. Joubert, J.-P. Lehner, M. Lièvre, H. Mathiex-Fortunet, M. Marty, F. Meyer, J. Micallef, M. Pigeon, B. Rouveix, F. Zannad
Publikováno v:
Therapies. 60:363-366
When a candidate drug is likely to become available to prescribers and healthcare policy makers, evaluation of therapeutic progress moves forward in two stages. First, the level of expected therapeutic progress must be established. This first stage r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2446a1470245c94f00281b5ebc7626a4
https://doi.org/10.2515/therapie:2005052
https://doi.org/10.2515/therapie:2005052